Skip to content

Marathon Pharmaceuticals submits deflazacort NDA to treat Duchenne muscular dystrophy

June 16, 2016

Marathon Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for its deflazacort investigational drug to treat Duchenne muscular dystrophy (DMD).

Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. It has fast track status, orphan drug designation and rare pediatric disease designation for DMD.

Click here to read more.